Analysis of the Risk Level and Severity of Potential Drug Interactions in Patients with Urinary Tract Infections Undergoing Hospitalization
DOI:
https://doi.org/10.30872/Keywords:
Drug Safety, Drug Combinations, Polypharmacy, Clinical ManagementAbstract
Urinary tract infections (UTIs) are among the most common bacterial infections and often require combination therapy, which has the potential to cause drug interactions that can compromise the effectiveness and safety of treatment. The simultaneous use of several drugs in patients with UTIs, especially in patients with comorbidities, increases the risk of drug interactions that affect clinical outcomes. This study aimed to determine the prevalence of potential drug interactions (PI-O), identify the most common types of interactions, and analyze the risk level and severity of drug interactions in hospitalized UTI patients. This study employed a retrospective descriptive method, using 93 medical records of UTI patients, and utilizing the Lexicomp® application. A total of 76 patients (81.72%) were identified as having potential drug interactions, with the combination of omeprazole and metamizole being the most common. Based on severity, most were classified as moderate (68.24%), and based on risk level, the majority were classified as category C (61.47%). These findings emphasize the importance of monitoring therapy, periodically evaluating drug regimens, and collaboration between doctors and pharmacists to prevent adverse clinical effects due to drug interactions.
References
[1] M. N. Mudhofar, H. Purnomo, and M. Mu’awanah, “Perawatan kateter urine dengan chlorhexidine gluconate 5% dalam mencegah infeksi saluran kemih,” Jurnal Keperawatan Mersi, vol. 13, no. 1, pp. 1–8, May 2024, doi: 10.31983/jkm.v13i1.10389.
[2] X. Yang, H. Chen, Y. Zheng, S. Qu, H. Wang, and F. Yi, “Disease burden and long-term trends of urinary tract infections: A worldwide report,” Front. Public Health, vol. 10, Art. no. 888205, 2022, doi: 10.3389/fpubh.2022.888205.
[3] W. Anggraini, T. M. Candra, S. Maimunah, and H. Sugihantoro, “Evaluasi kualitatif penggunaan antibiotik pada pasien infeksi saluran kemih dengan metode Gyssens,” Keluwih: Jurnal Kesehatan dan Kedokteran, vol. 2, no. 1, pp. 1–8, Dec. 2020, doi: 10.24123/kesdok.V2i1.2876.
[4] N. Audina, J. F. Suparningtyas, and H. Herman, “Kajian potensi interaksi obat pada pasien infeksi saluran kemih di RSUD Inche Abdoel Moeis Samarinda periode tahun 2021,” Jurnal Sains dan Kesehatan, vol. 5, no. SE-1, pp. 27–32, 2023, doi: 10.25026/jsk.v5iSE-1.2051.
[5] S. Noor, M. Ismail, and F. Khan, “Potential drug-drug interactions in patients with urinary tract infections: A contributing factor in patient and medication safety,” Front. Pharmacol., vol. 10, Art. no. 1032, Sep. 2019, doi: 10.3389/fphar.2019.01032.
[6] N. Sinata, I. D. Pratiwi, and R. Rusnedy, “Potensi interaksi obat pada pasien infeksi saluran kemih sistitis tahun 2021 di RSUD Arifin Achmad Provinsi Riau,” Jurnal Mandala Pharmacon Indonesia, vol. 9, no. 2, pp. 524–531, Dec. 2023, doi: 10.35311/jmpi.v9i2.430.
[7] H. F. F. Rachim and A. Y. Nugraheni, “Evaluasi drug related problems pada pasien infeksi saluran kemih rawat inap di Rumah Sakit Daerah Surakarta tahun 2022,” Usadha Journal of Pharmacy, pp. 123–137, May 2024, doi: 10.23917/ujp.v3i2.319.
[8] J. Shareef, S. B. Sridhar, A. N. Ahmad Ismail, P. G. M. Rao, and R. Ain Ur, “Assessment of potential drug-drug interactions in hospitalized patients with infectious diseases: An experience from a secondary care hospital,” F1000Research, vol. 13, Art. no. 164, 2025, doi: 10.12688/f1000research.143186.4.
[9] N. R. Hidayati, S. Indriaty, A. Bachtiar, I. Setyaningsih, M. Y. Zamzam, and V. Michelle, “Study of potential drug interactions in patients with urinary tract infections at the inpatient,” Medical Sains: Jurnal Ilmiah Kefarmasian, vol. 7, no. 1, pp. 9–20, Mar. 2022, doi: 10.37874/ms.v7i1.272.
[10] O. M. Sari and A. M. P. Putra, “Severity and risk rating of drug-drug interaction potency in chronic kidney disease in public health hospital,” Journal of Pharmaceutical Care, vol. 12, no. 2, pp. 78–87, Jun. 2024, doi: 10.18502/jpc.v12i2.16185.
[11] Lexicomp, Drug Interaction Checker. Wolters Kluwer Lexicomp, 2024. [Online]. Available: https://www.wolterskluwer.com/en/solutions/lexicomp/lexicomp
[12] H. Anggreini, Lamri, and M. J. Saputri, “Pola infeksi bakteri saluran kemih pada spesimen urin pasien diabetes mellitus di ruang rawat inap RSUD A. W. Sjahranie tahun 2020–2021,” Jurnal Labora Medika, vol. 7, no. 2, pp. 48–55, 2023.
[13] K. P. Seputra et al., Panduan Tatalaksana Infeksi Saluran Kemih dan Genitalia Pria, 3rd ed. Jakarta, Indonesia: Ikatan Ahli Urologi Indonesia, 2020.
[14] Y. W. Permadi et al., “Analisis polifarmasi terhadap interaksi obat di Rumah Sakit Umum Kota Pekalongan,” Lambda: Jurnal Pendidikan MIPA dan Aplikasinya, vol. 5, no. 1, pp. 69–82, 2025, doi: 10.58218/lambda.v5i1.1189.
[15] O. M. Sari and A. M. P. Putra, “Identification of probable drug-drug and drug-food interactions in hospitalized patients with chronic renal disease,” Pharmacology and Clinical Pharmacy Research, vol. 9, no. 2, pp. 130–141, Dec. 2024, doi: 10.15416/pcpr.v9i2.56525.
[16] O. M. Sari, A. M. P. Putra, Y. Wasiaturrahmah, and N. Rahmah, “Analisis faktor yang berhubungan dengan potensi interaksi obat pasien COVID-19 di salah satu rumah sakit Kalimantan Selatan,” Jurnal Sains dan Kesehatan, vol. 5, no. 5, Art. no. 5, Aug. 2023, doi: 10.25026/jsk.v5i5.1811.
[17] F. Bachmann et al., “Metamizole is a moderate cytochrome P450 inducer via the constitutive androstane receptor and a weak inhibitor of CYP1A2,” Clinical Pharmacology and Therapeutics, vol. 109, no. 6, pp. 1505–1516, 2021, doi: 10.1002/cpt.2141.
[18] R. Tofure, L. B. S. Huwae, and E. Astuty, “Karakteristik pasien penderita neuropati perifer diabetik di Poliklinik Saraf RSUD Dr. M. Haulussy Ambon tahun 2016–2019,” Molucca Medica, vol. 14, pp. 97–108, 2021, doi: 10.30598/molmed.2021.v14.i2.97.
[19] A. D. Maria, M. Rizki, S. S. Mahfud, S. S. Nurfauziah, Amalia, M. Arfania, and D. Frianto, “Efek samping yang ditimbulkan dari interaksi obat bagi penderita stroke iskemik maupun hemoragik: Review artikel,” INNOVATIVE: Journal of Social Science Research, vol. 3, no. 2, pp. 9785–9798, 2023.
[20] R. Amelia, S. Hasanuddin, and N. H. Nasir, “Analisis drug related problems penggunaan antibiotik pada pasien anak dengan diare di BLU RSUD Kabupaten Bombana periode Januari–Juli tahun 2023,” Jurnal Pharmacia Mandala Waluya, vol. 4, no. 1, pp. 45–55, 2025, doi: 10.54883/jpmw.v4i1.244.
[21] R. Pinkoh, R. Rodsiri, and S. Wainipitapong, “Retrospective cohort observation on psychotropic drug-drug interaction and identification utility from 3 databases: Drugs.com®, Lexicomp®, and Epocrates®,” PLOS ONE, vol. 18, no. 6, Art. no. e0287575, 2023, doi: 10.1371/journal.pone.0287575.
[22] M. Aghili and M. N. Kasturirangan, “Management of drug–drug interactions among critically ill patients with chronic kidney disease: Impact of clinical pharmacist’s interventions,” Indian Journal of Critical Care Medicine, vol. 25, no. 11, pp. 1226–1231, 2021, doi: 10.5005/jp-journals-10071-23919.
[23] V. D. Suryani, N. U. Purwanti, and Nurmainah, “Narrative review: Efek samping penggunaan antibiotik azitromycin pada pasien COVID-19,” Indonesian Journal of Pharmaceutical Education, vol. 3, no. 2, pp. 325–335, 2023, doi: 10.37311/ijpe.v3i2.20720.
[24] D. A. Juwita, F. Rachmaini, Almahdy, R. Abdillah, and Y. M. Wati, “The comparison between combination of candesartan-amlodipine and candesartan-furosemide on blood pressure in hypertensive patients with chronic kidney disease,” Pharmaciana, vol. 12, no. 2, pp. 218–226, 2022, doi: 10.12928/pharmaciana.v12i2.21491.
[25] D. Wijaya, “A review of the interactions of clopidogrel drugs with proton pump inhibitors (PPIs) in the treatment of cardiovascular events,” Jurnal Kedokteran Meditek, vol. 27, no. 2, pp. 190–196, 2021, doi: 10.36452/jkdoktmeditek.v27i2.1966.
[26] I. Aslama, R. K. Sinuraya, N. Zakiyah, and T. I. Dewi, “The clinical impact of drug interaction between clopidogrel and proton pump inhibitors: A narrative review,” Journal of Pharmaceutical and Sciences, vol. 8, no. 4, pp. 2531–2540, 2025, doi: 10.36490/journal-jps.com.v8i4.1040.
[27] A. K. Sahoo, A. Singh, D. Gupta, S. Dhaneria, and P. Arunima, “Assessment of potential drug-drug interactions (pDDIs) and their risk factors among hospitalized cardiac patients in a tertiary-care center of Central India: A retrospective record-based study,” Hospital Pharmacy, vol. 59, no. 1, pp. 24–31, 2024, doi: 10.1177/00185787231182569.
[28] Ganavi, J. V. Nagaral, Deepak, Sahana, Vishali, and Babitha, “The potential drug-drug interactions between antibiotics and other prescribed medications in a tertiary care centre,” Journal of Population Therapeutics & Clinical Pharmacology, vol. 32, no. 4, pp. 1047–1053, 2025, doi: 10.53555/f1gbha15.
[29] D. M. Sulaiman, S. S. Shaba, H. B. Almufty, A. M. Sulaiman, and M. A. Merza, “Screening the drug-drug interactions between antimicrobials and other prescribed medications using Google Bard and Lexicomp® Online™ database,” Cureus, vol. 15, no. 9, pp. 1–8, 2023, doi: 10.7759/cureus.44961.
[30] Ş. Benligil, E. Demirpolat, A. U. Kılıc, and K. Gundoğan, “Evaluation of potential drug-drug interactions caused by antibacterial and antifungal drugs in the intensive care unit: A retrospective cross-sectional study,” Journal of Erciyes University Faculty of Medicine, vol. 45, no. 6, pp. 603–613, 2023, doi: 10.14744/cpr.2023.02996.
[31] Y. Arslan et al., “Point-prevalence of antimicrobial-related potential drug-drug interactions in hospitalized older adults: A multicenter study using Lexicomp,” Journal of Clinical Medicine, vol. 15, no. 3, pp. 1–16, 2026, doi: 10.3390/jcm15031163.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Jurnal Sains dan Kesehatan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
